Serina Therapeutics ( (SER) ) has provided an announcement.
On March 24, 2025, Serina Therapeutics announced that its Chief Development Officer, Randall Moreadith, presented new data at the American Chemistry Society Spring 2025 Meeting. The presentation highlighted the non-immunogenic profile of Serina’s POZ-lipid technology, which did not trigger an antibody response in rats, unlike the commonly used PEG-lipid standards. This discovery could lead to safer and more effective lipid nanoparticle formulations for gene therapy and RNA-based medicines, potentially impacting the development of treatments that avoid adverse immune reactions.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, focusing on developing drug product candidates for neurological diseases and other indications. The company utilizes its proprietary POZ Platform™ to enhance the efficacy and safety of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates.
YTD Price Performance: -5.88%
Average Trading Volume: 13,736
Technical Sentiment Signal: Buy
Current Market Cap: $42.68M
For a thorough assessment of SER stock, go to TipRanks’ Stock Analysis page.